Video: Who Am I?| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Search results for: health insurance

Shingles Vaccination Not at Goal Levels for U.S. Seniors

Madeline Kennedy  |  

(Reuters Health)—Just one in five people over age 60 in the U.S. have been vaccinated against a painful eruption of herpes zoster (shingles), despite recommendations that all of them should get the shot. It’s estimated that among people over age 50, one in three will eventually develop shingles. After age 80, half of adults have…

Anthem May Trim Obamacare Participation in 2018

By Caroline Humer and Ankur Banerjee  |  

(Reuters)—U.S. health insurer Anthem Inc on Wednesday raised the prospect of smaller participation in the individual Obamacare exchanges in 2018, saying it would have a market-by-market strategy that hinges on 2017 profitability. The company said that losses due to sicker-than-expected customers in its individual Obamacare plans were a bit less than foreseen in the third…

Brave New MACRA World

  |  

Sweeping changes in how physicians are paid for patient care are on the way. The Medicare Access and Children’s Health Insurance Program (CHIP) Reauthorization Act of 2015, or MACRA, tossed out the Sustainable Growth Rate formula and ties reimbursement to quality measures. A Helpful Presentation Because 2017 is the first performance year under the new…

Crossing the Line

When Medical Workforce Grievances Lead to Strikes

  |  

Picket Lines: June 27 was marked on my calendar as the day to watch. No doubt the union organizers shrewdly selected it to be their strike day because of its proximity to July 1, an auspicious date for teaching hospitals, when rookie interns and residents anxiously assume their heightened roles of responsibility within the medical…

Ethics Forum: Prescribing Teratogenic Medications to Adolescents Can Raise Confidentiality, Ethical Concerns

Karen B. Onel, MD, & Melissa Tesher, MD  |  

Case A 17-year-old girl returns to the rheumatology clinic for scheduled follow-up for systemic lupus erythematosus (SLE). She is accompanied by her mother and father. She has a history of autoimmune cytopenias and Class III lupus nephritis. She has responded well to treatment with mycophenolate mofetil and hydroxychloroquine and was successfully weaned off of prednisone…

Possible Impact of Biosimilar Infliximab on U.S. Market in Prescriptions, Pricing

  |  

The use of biosimilars for rheuma­tology in the U.S. became a reality when the U.S. Food and Drug Administration (FDA) approved Inflectra (infliximab-dyyb), a biosimilar to Remicade (infliximab), in April. What this may mean is increased competition among drug companies with regard to pricing and, therefore, potentially lower costs for U.S. patients, according to Seoyoung…

Blacks, Asians at Higher Risk for Allopurinol-Related Skin Reactions

Deborah Levenson  |  

Be careful when prescribing allo­purinol to black and Asian gout patients, a study newly advises. Black and Asian patients who take this ubiquitous, more-than-40-year-old medication are at much higher risk of certain serious skin reactions than are Caucasians or Hispanics. Compared with Caucasians, blacks who take allopurinol to lower blood urate levels have an increased…

Placebo Outperforms Glucosamine/Chondroitin Sulfate for Knee OA

Erin Blakemore  |  

(Reuters Health)—Glucosamine sulfate and chondroitin sulfate are not more beneficial than placebo treatments for patients with knee osteoarthritis, a recent trial suggests. In a double-blind study, researchers investigated the efficacy of a medicine that delivered both glucosamine and chondroitin sulfate. The 164 participants all had osteoarthritis and moderate to severe knee pain. Half the participants…